CTOs on the Move

Avanti Hospitals

www.avantihospitals.com

 
Avanti Hospitals currently owns and operates four acute care hospitals: East Los Angeles Doctors Hospital, Memorial Hospital of Gardena, Community Hospital of Huntington Park, and Coast Plaza Hospital, all located near Los Angeles, California. Our mission is to provide affordable, high quality healthcare services to our community with consistency and compassion. Avanti is committed to cooperating with and supporting the long-term needs and objectives of each community we serve. We understand the impact we have on our communities and the potential to improve overall health. We have worked hard to establish a reputation of quality and trust in our communities, ...
  • Number of Employees: 250-1000
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

21st Century Scientific

21st Century Scientific is a Coeur D Alene, ID-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Pharmaceutical Resource

Pharmaceutical Resource, Corp. is a Hatboro, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Inteleso

Inteleso is a Orlando, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Medevco

Medevco is a Dallas, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kymera Therapeutics

Kymera is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. Kymera’s proprietary targeted protein degradation platform, called Pegasus, enables us to discover highly selective small molecule protein degraders with activity against disease-causing proteins throughout the body. We believe that our small molecule protein degraders have significant advantages over existing therapies and allow us to address a large portion of the human genome that was previously intractable with traditional modalities. Kymera focuses on biological pathways that have been clinically validated but where key biological nodes/proteins have not been drugged or have been inadequately drugged. To date, we have utilized our Pegasus platform to design novel protein degraders focused in the areas of immunology-inflammation and oncology, and continue to apply our platform’s capabilities to additional therapeutic areas.